Veracyte, Inc.

NASDAQ:VCYT

Biotechnology

Healthcare
$25.57 +3.56%

+$1.83 today

Market cap
$2.06B
Beta
1.98
P/E (TTM)
48.0
EPS (TTM)
$1.11
52W Low $22.61High $53.66

Volume 2.45M

Average 1.05M

VCYT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Veracyte, Inc.NASDAQ: VCYT

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $29.44M rose 81.0% year over year, ahead of the +31.8% change in trailing-twelve-month research & development. Sequentially, it rose 8.7% from the prior quarter. Over 3 fiscal years it compounded at +20.4% a year.

Context

  • Research & development amounted to 13.7% of revenue in FY2025, down 1.9 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +81.0% holds above the trailing-twelve-month pace of +31.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$29.44M+8.7% QoQ
Last fiscal yearDec 2025
$70.81M+2.2% YoY
LTMJun 2026
$93.37M+31.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+81.0%——
1 year+2.2%——
3-year CAGR+20.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
70.81M USD
Year-over-year change
+2.2%
4-year CAGR
+24.1%

Research & Development vs competitors

How VCYT compares with its peers on the latest reported figures

  • VCYT's LTM Jun 2026 research & development of $93.37M is the 3rd highest of the 10 companies compared; the peer median is $53.69M.
  • Its year-over-year change of +31.8% is the 4th highest of 10, against a peer median of +9.5%.
  • Research & development amounts to 16.6% of revenue for VCYT, versus a peer median of 15.8%.
VCYT Competitors Peer median
Research & Development for VCYT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$386.67M +7.6%-0.9%30.2%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
VCYTVeracyte, Inc.LTM Jun 2026$93.37M +31.8%+20.4%16.6%
WGSGeneDx Holdings Corp.LTM Jun 2026$83.32M +64.3%-5.8%18.3%
BLLNBillionToOne, Inc.LTM Jun 2026$59.21M +38.6%—14.9%
CSTLCastle Biosciences, Inc.LTM Mar 2026$53.69M +5.8%+4.9%15.8%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.59M +68.3%+29.6%902.4%
BDSXBiodesix, Inc.LTM Mar 2026$12.42M +19.5%-2.9%12.9%
Peer median (excluding VCYT) $53.69M+9.5%+2.0%15.8%

Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.51M296.54M361.05M445.76M517.15M
Cost of Revenue74.4M101.58M112.9M147.62M157.1M
Gross Profit145.11M194.95M248.15M298.15M360.05M
Gross Margin66.1%65.7%68.7%66.9%69.6%
Research & Development29.84M40.6M57.31M69.29M70.81M
Selling, General & Admin181.19M174.08M184.23M206.04M210.95M
Operating Expenses227.02M236.04M333.94M282M285.9M
Depreciation & Amortization19.59M25.93M27.19M23.46M21.42M
EBITDA(61.82M)(10.3M)(49.41M)49.21M89.62M
EBITDA Margin-28.2%-3.5%-13.7%11.0%17.3%
Operating Income(81.9M)(41.08M)(85.8M)16.14M74.15M
Operating Margin-37.3%-13.9%-23.8%3.6%14.3%
Interest Income135K1.97M7.34M11.15M0
Interest Expense241K198K15K2K0
Other Income / Expenses254K4.65M9.18M9.6M(5.95M)
Income Before Tax(81.65M)(36.43M)(76.61M)25.74M68.2M
Pre-Tax Margin-37.2%-12.3%-21.2%5.8%13.2%
Income Tax Expense(6.09M)133K(2.21M)1.61M1.85M
Net Income(75.56M)(36.56M)(74.4M)24.14M66.35M
Net Margin-34.4%-12.3%-20.6%5.4%12.8%
EPS (Basic)(1.11)(0.51)(1.02)0.320.84
EPS (Diluted)(1.11)(0.51)(1.02)0.310.82
Weighted Avg Shares67.89M71.55M72.64M76.48M78.58M
Weighted Avg Shares (Diluted)67.89M71.55M72.64M78.16M80.57M

Veracyte, Inc.

NASDAQ:VCYT

Intrinsic Alpha fair value

Locked

Current Price

$25.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.